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Abstract
Background: Parkinson’s disease (PD) has been linked with exposure to a variety of environmental and
immunological insults (for example, infectious pathogens) in which inflammatory and oxidative processes seem to
be involved. In particular, epidemiological studies have found that pesticide exposure and infections may be linked
with the incidence of PD. The present study sought to determine whether exposure to a viral mimic prior to
exposure to pesticides would exacerbate PD-like pathology.
Methods: Mice received a supra-nigral infusion of 5 μg of the double-stranded RNA viral analog, polyinosinic:
polycytidylic acid (poly(I:C)), followed 2, 7 or 14 days later by administration of the pesticide, paraquat (nine 10
mg/kg injections over three weeks).
Results: As hypothesized, poly(I:C) pre-treatment enhanced dopamine (DA) neuron loss in the substantia nigra pars
compacta elicited by subsequent paraquat treatment. The augmented neuronal loss was accompanied by robust signs
of microglial activation, and by increased expression of the catalytic subunit (gp91) of the NADPH oxidase
oxidative stress enzyme. However, the paraquat and poly(I:C) treatments did not appreciably affect home-cage
activity, striatal DA terminals, or subventricular neurogenesis.
Conclusions: These findings suggest that viral agents can sensitize microglial-dependent inflammatory responses,
thereby rendering nigral DA neurons vulnerable to further environmental toxin exposure.
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Background
The neurodegenerative process that occurs in Parkinson’s
disease (PD) appears to be complex, involving mitochon-
drial and ubiquitin-processing defects, along with altera-
tions of oxidative, apoptotic, and trophic factors [1-5]. One
common mechanism that could link virtually all pro-death
pathways in PD is the microglial-dependent neuroinflam-
matory processes that are typically induced in the substania
nigra pars compacta (SNc) of patients with PD, and in nu-
merous animal models of the disease [6-8]. Moreover, in-
creasing evidence supports the notion that cumulative
multiple environmental toxin ‘hits’, (for example, pesti-
cides, heavy metals, and infectious pathogens) over time
might act as triggers for PD through their effects upon
neuroinflammatory cascades [9,10], possibly in conjunc-
tion with genetic vulnerabilities.
It is possible that exposure to one environmental toxin
‘hit’ sensitizes neuroinflammatory or pro-death pathways,
rendering nigrostriatal dopamine (DA) neurons more vul-
nerable to various secondary insults [11-13]. In fact, it has
been shown that prenatal exposure to the bacterial endo-
toxin known as lipopolysaccharide (LPS) enhanced the vul-
nerability of SNc DA neurons to later pesticide exposure in
adulthood [14]. Our own work similarly showed an aug-
mented loss of DA neurons and protracted microglial acti-
vation in adult mice primed with a single low dose of LPS
followed by later treatment with the pesticide paraquat
[12]. Whatever the case, immunocompetent brain micro-
glia are crucially involved in responding to all types of for-
eign insults and are likely key players in modulating
neurodegenerative pathways.
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Microglia possess Toll- like receptors (TLRs) which
recognize pathogen-associated molecular patterns (PAMPs)
found on microbes [15,16]. TLRs are ubiquitously
expressed in peripheral leukocytes and microglia, and to a
lesser extent astrocytes, oligodendrocytes and possibly even
neurons [15]. TLR4 typically recognizes pathogens of a bac-
terial nature, whereas the TLR3 pathway is engaged by viral
pathogens or viral- like challenges, such as double-stranded
RNA, and both TLR pathways promote pro-inflammatory
cytokines, chemokines, and oxidative factors [15,17].
Although TLR regulation is essential for maintaining
homeostasis, excessive TLR engagement has been linked to
inflammatory and neurodegenerative diseases, including
Alzheimer’s disease, multiple sclerosis, and ischemic stroke
[17-20].
Although little is known about the interaction of
viral TLR mechanisms and PD, a few studies have
reported correlations between PD-like symptoms or
post-encephalic parkinsonism and a variety of viral
infections [21-24]. More recently, experimental evi-
dence indicated that the H5N1 virus induced PD-like
motor disturbances, increased α-synuclein phosphor-
ylation, and resulted in a loss of SNc DA neurons in
rodents [23]. Similarly, administration of the viral mi-
metic and TLR3 agonist, polyinosinic: polycytidylic
acid (poly(I:C)), induced long-term glial activation in
the SNc and the striatum [25].
In this study, we assessed whether exposure to the viral-
like challenge poly(I:C),would enhance the neurodegenera-
tive effects of later treatment with paraquat, and whether
any such effects were associated with the microglial and
oxidative status of the animals. Our findings do support the
contention that DA neurons are especially vulnerable to en-
vironmental insults when exposure occurs in the context of
an activated microglial microenvironment stemming from
viral challenge. However, the SNc pathology induced by
poly(I:C) and paraquat appeared to occur in the absence of
permanent behavioral or striatal deficits. These data also
indicate that the duration of the augmented microglial
response induced by pre-treatment with a TLR3 agonist
(poly(I:C)) pre-treatment followed by paraquat administra-
tion exceeded what we previously with TLR4 stimulation
(using LPS) performed before the pesticide [12]. Hence,
viral and bacterial insults have the potential to interact with
an environmental toxin to differentially affect the microglial
state and extent of SNc pathology.
Methods
All experimental tests were approved by the Carleton
University Committee for Animal Care and were con-
ducted in adherence to the guidelines stipulated by the
Canadian Council for the use and care of animals in
research.
Animals
Male C57BL/6 mice (Charles River, Laprarie, Quebec,
Canada) were obtained at 10–12 weeks of age and given 1
week to acclimatize to their new conditions before experi-
mentation. Animals were housed singly in standard poly-
propylene cages, and maintained on a 12 hour light/dark
cycle. Mice were provided with food and water ad libitum,
and temperature and humidity were controlled in the
rooms.
Cannulation and infusion
Animals underwent stereotaxic cannula implantation
(described below), with the cannulae situated directly above
the SNc, and were given 1 week to convalesce before ex-
perimentation. Mice were then infused with the TLR3
agonist, poly(I:C) (5 μg/2 μl) (InvivoGen, San Diego, CA,
USA) or saline. After the infusions, mice (n=8) received
intraperitoneal injections with paraquat (1,1′-dimethyl-
4,4′-bipyridinium dichloride; 10 mg/kg; Sigma-Aldrich,
Oakville, ON, Canada,), or an equivalent volume of saline
(Sigma-Aldrich, Oakville, ON, Canada), three times per
week for 3 weeks, giving a total of nine injections, as previ-
ously described [26,27]. Mice began receiving the paraquat
or saline injections at 2, 7, or 14 days after intra-SNc poly(I:
C) or saline infusion in order to investigate whether varying
exposure times differentially affect paraquat toxicity. Treat-
ment groups are summarized in Table 1.
Surgery
Animals underwent cannula implantation surgery as previ-
ously described [27]. Briefly, mice were anesthetized with
oxygen-enriched isoflurane, and placed in a stereotaxic ap-
paratus. All mice were then implanted with indwelling can-
nulae directly above the SNc (bregma: anterior–posterior
−3.16 mm, ± lateral 1.2 mm, ventral −4.0 mm). Animals
were given 1 week to convalesce after surgery before ex-
perimentation began. Infusions were delivered through
polyethylene tubing connected to a microliter syringe
(Hamilton; Reno, NV, US) and syringe pump (Harvard
Apparatus Pico Plus; Holliston, MA, US). The drug was
dissolved in 2 μl of saline and delivered over a 5-minute
period, followed by a 2-minute pause to ensure proper
Table 1 Breakdown of groups as a function of saline, poly





Injection Time before tissue
harvest, days
1 Saline 2 Saline 7
2 Saline 2 PQ 7
3 Poly I:C 2 Saline 7
4 Poly I:C 2 PQ 7
5 Poly I:C 7 PQ 7
6 Poly I:C 14 PQ 7
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delivery. Infusions were conducted between 08.30 and
14.00 hours to avoid variability attributed to diurnal varia-
tions. Furthermore, animals were unrestrained during the
infusion process to minimize stress.
Behavioral analysis
Home-cage locomotor activity was monitored during a
complete 12-h light/dark cycle using an infrared beam-
break apparatus (Micromax; Accuscan Instruments,
Columbus, OH, USA). Locomotor activity was measured
during the third and fourth weeks of experimentation (15
and 22 days after the infusion), and 24 hours before being
killed. Animals were given 1 hour to acclimatize to the
room prior to assessment. Total locomotor activity was
assessed by recording the number of infrared beam-breaks
over a 24-hour period, as described previously [28].
Motor coordination was examined by way of a pole test,
as previously described [29,30]. This test consists of a pole
500 mm pole in length and 8 mm in diameter, with a plas-
tic ball at the top. The pole was covered with non-toxic ad-
hesive tape to increase traction for the animals. Home-cage
bedding was placed at the bottom of the pole to encourage
the animals to descend. Animals were placed head upward
directly below the plastic ball. Motor coordination is neces-
sary for the mouse to rotate downward and climb to the
ground. Latency to rotate 180o and latency to climb down
the pole was recorded, with maximum test duration set at
90 seconds. Testing was conducted under dim lighting con-
ditions between 09.00 and 1400 hours on the day after the
second infrared recording (23 days after the infusion). The
animals were recorded for three trials, with a 1 minute rest
period between tests.
Immunohistochemical analysis
Animals were killed with an overdose of sodium pentobar-
bital injection on the seventh day after the final injection,
and perfused with ice-cold saline followed by 4% parafor-
maldehyde. The whole brain was dissected out and stored
in 0.1 mol/L PBS with 20% sucrose solution and 0.02%
sodium azide at 4°C until further analysis.
Fixed brains were cut on a cryostat into coronal sections
20 μm thick, and the striatum and SNc secions were
mounted directly onto gelatin-coated slides, then analyzed
for tyrosine hydroxylase (TH) staining as a representative
measure of nigrostriatal DA neurons. SNc sections were
also stained for the microglial and oxidative stress markers,
CD11b and gp91, respectively.
To provide an index of potential neuroplastic changes
that could influence behavioral outputs, striatal sections
were stained for doublecortin (DCX). Sections were
incubated overnight at 4°C in mouse anti-TH (1:1000,
ImmunoStar), rat anti-CD11b (1:1000, AbDSerotec), goat
anti-gp91 (1:1000) or goat anti-DCX (1:1000) (both Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Sections were
further incubated for 2 hours at room temperature with
their respective biotinylated antibodies: biotin anti-mouse
(1:500), biotin anti-rat (1:500),or biotin anti-goat (1:1000)
(all Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA). Primary and secondary antibodies were
diluted in 0.01 mol/l PBS (pH 7.3) containing 2% BSA with
0.3% Triton X-100 and 0.01 sodium azide. Sections were
further incubated in horseradish peroxidase-conjugated
streptavidin tertiary antibody (1:1000 for gp91 and DCX,
1:500 for TH and CD11b; Jackson ImmunoResearch) at
room temperature for 2 hours and dissolved in 0.01 mol/l
PBS (pH 7.3) containing 2% BSA and 0.3% Triton X-100.
Antibodies were visualized by incubation with DAB
(Sigma-Aldrich) for 10 minutes on a shaker table. TH-
stained SNc sections were further counterstained with cre-
syl violet (Sigma-Aldrich).
The microglial state of activation on CD11b-stained sec-
tions was rated using a previously described scale [12]. In
brief, cells were rated on a scale of 0–3, where 0 reflects the
lowest state of activation (microglia are in their ‘resting
state’, identified by highly ramified, thin processes); 1 indi-
cates an intermediate state of activation (fewer than 10 cells
within the SNc are moderately activated.); 2 indicates
higher activation (more than half of the visible cells were in
an intermediary or active state, characterized by rounded
soma and no or few processes) and 3 indicates sections
showing the highest level of activation (majority of cells
exhibited a very active state).
In addition, gp91 reactivity was rated on a similar scale:
0 reflected little to no gp91 reactivity; 1 indicated low to
moderate gp91 immunostaining (gp91-positive microglial
cells were present in relatively low numbers); 2 signified
increased gp91 staining (numerous strongly reactive
microglia present).
All ratings (both CD11b and gp91) were conducted twice
by the same person, who was blinded to all treatments. The
ratings yielded an inter-rating reliability of over 90% , and
all scores per section were averaged to give an overall repre-
sentation of total nigral glial cell and oxidative activity
(CD11b and gp91, respectively).
Quantification of tyrosine hydroxylase-positive neurons
Quantification of SNc DA-producing neurons was
achieved by serial section analysis of the number of SNc
TH-positive cells, at bregma levels −3.08, -3.16, -3.28,
-3.40, and −3.52. Using a double-blind procedure, the total
number of TH-positive neurons was counted across mul-
tiple bregma levels for each animal in each of the treat-
ment groups. Midbrain TH-positive counts from each
bregma level and animal were compared across treatment
groups. The same midbrain sections were also used to
evaluate the total number of TH-negative cells, which
represents the number of surviving neurons. Cresyl violet-
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stained neurons from each bregma level and animal were
quantified and compared across treatment groups.
Striatal quantification photomicrographs were obtained
for each animal using the same exposure time. Image J
software was used to determine the background threshold
for each striatal section and the total number of white
(background) and black (TH-positive) pixels. All images
were converted into an eight-bit format, where the gray-
scale varied from 0 to 255. The area of interest was
selected and the upper and lower threshold values were
used across all images to separate the features of interest
from the background. The upper and lower thresholds
were determined using an automatic thresholding option,
a modified version of the IsoData method. This algorithm
divides the image into the object of interest and back-
ground by taking an initial threshold (histogram-derived),
followed by the averages of the pixels at or below the
threshold, and then the pixels above are computed. The
averages of those two values are computed, the threshold
is incremented, and the process is repeated until the
threshold is larger than the composite average. The data
were then presented as a histogram with the number of
black (object of interest) and white (background) pixels
present.
Statistical analysis
Home-cage activity was assessed using a mixed repeated-
measures analysis of variance (ANOVA) with paraquat
and poly(I:C) treatment effects evaluated over time. All
other data were analyzed by standard ANOVA, followed
by Fisher’s planned comparisons (P< 0.05) where appro-
priate. Data were evaluated using StatView statistical soft-




A mixed factor (time× treatment) ANOVA failed to reveal
any significant difference in home-cage behavior in re-
sponse to the paraquat and poly(I:C) treatments over time.
Specifically, there was no significant time× treatment inter-
action nor was there an effect for time alone (F(10,72) = 0.59;
F(2,72) = 1.77, respectively, P> 0.05). Similarly, the main ef-
fect for treatment did not reach significance (F(5,72) = 2.07,
P=0.09). However, it was clear that there was a trend to-
wards reduced home-cage activity; particularly at the
second time point (that is, 22 days after the initial infusion)
(Figure 1).
Quantification of tyrosine hydroxylase-positive neurons
Nigral DA cell bodies were counted at bregma levels −3.08,
-3.16, 3.28, -3.40, and −3.52 for all treatment groups. Owing
to unequal sample sizes across bregama levels stemming
from a loss of some tissue sections at levels −3.16 and −3.52
(resulting in unbalanced analyses), a repeated-measures
ANOVA was not conducted. However, separate ANOVAs
for each level of the SNc did reveal that the number of nigral
TH-positive neurons varied as a function of treatment at
bregma levels −3.08, −3.28, −3.40 and −3.52 (F5,29) =8.67, P
< 0.05; F(5,30) =4.654, F(5,23) = 2.825, F(5,24) =3.724, P <0.05,
respectively). However, significant variability at bregma level
−3.16 precluded finding any significant difference at this par-
ticular SNc level (F(5,21) =1.560, P=0.22). Groups treated
with paraquat or poly(I:C) alone showed a modest, but non-
significant decrease in SNc DA neurons (approx. 10 to 15%;
Figure 2). However, poly(I:C) priming followed by subse-
quent paraquat administration led to a significant decrease
in SNc DA neurons (25 to 50% relative to saline-treated
controls; P< 0.05). Moreover, this effect was apparent when
intervals of either 2, 7 or 14 days were interspersed between
the poly(I:C) priming and subsequent initiation of the para-
quat regimen.
To ascertain whether the loss of TH-positive staining
reflected a genuine neurodegenerative effect and whether
the effect of paraquat was limited to DA neurons, all slides
were counterstained with cresyl violet. Quantification of
SNc cresyl violet-stained TH-negative neurons showed no
significant differences between treatment groups (F
(5,28) = 0.804, P> 0.05, F(5,29) = 1.791, P> 0.05; bregma
levels −3.08 and −3.28, respectively; Figure 3). Hence, it
appears that the effects of paraquat were more selective
for TH-positive neurons, and that this was a genuine neu-
rodegenerative effect. Indeed, increased cresyl violet TH-
negative neuronal numbers would be expected if paraquat
Figure 1 Total home-cage locomotor activity was monitored
for 24 hours at three separate time points: 15 and 22 days
after poly(I:C) infusion, and 24 hours before animals were
killed. No significant differences were seen between treatment groups
at any of the time intervals. However, there was a trend towards
reduced activity at the middle time point (22 days). Data are expressed
as a mean±SEM; n= 8 to 15 Analysis of pole-test performance was
used to investigate any PD-like hindlimb and forelimb coordination
deficits that might have been induced by paraquat with or without
poly(I:C) priming. The pole test was conducted once, during the
second week after saline/poly(I:C) infusion. Latency to turn and latency
to pole descent were both recorded for three trials. No behavioral
difference were found for either of the measures across treatment
groups (Fs(5,42)< 1, P> 0.05; data not shown).
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were simply inducing a suppression of TH expression in
the absence of neuronal loss. However, if anything, para-
quat provoked a trend towards reduced TH-negative
neuronal counts that was reminiscent of that observed for
the TH-positive DA neurons. Furthermore, combined ex-
posure to poly(I:C) and paraquat caused a more marked
effect. Specifically, post hoc comparisons showed that mice
that received paraquat 2 days after poly(I:C) infusion dis-
played reduced TH-negative levels (at bregma level 3.28),
relative to their saline-treated counterparts (P< 0.05).
Thus, although the effects were much more pronounced
for TH-positive SNc neurons, poly(I:C) infusion plus para-
quat treatment appeared to affect non-DAergic neurons
also.
Microglial assessment
Morphological changes in microglia were determined as a
means of indicating differing degrees of glial activation, as a
representation of the inflammatory state of the SNc.
ANOVA showed that microglial ratings of morphological
appearance approached significance as a function of the
poly(I:C) and paraquat treatments (F(5,19) = 2.596, P=0.05).
Fisher’s post hoc comparison showed that although para-
quat and poly(I:C) alone did not affect microglial ratings,
enhanced ratings of glial morphology were evident in mice
that were pre-treated with the viral analog and then later
exposed to the pesticide (P< 0.05; Figure 4). However, as
was the case for the TH-positive neuronal counts, the time
interval between the poly(I:C) and paraquat treatments did
Figure 2 Substania nigra pars compacta (SNc) tyrosine hydroxylase (TH) + neurons were quantified from multiple bregma levels.
Paraquat and poly(I:C) alone caused a modest, but non-significant TH+ reduction relative to saline-treated controls. However, pre-treatment with
poly(I:C) followed by paraquat induced a significant reduction in TH+ neuronal counts at all bregma levels and at all re-exposure intervals. (A)
Representative photomicrographs showing the degree of nigral TH+ neuron loss in paraquat, poly(I:C), and the combination treatment groups
compared with saline-treated controls. (B) Quantification of SNc TH+ neuronal counts depicted in bar graphs. *P< 0.05, relative to saline-treated
controls. All data expressed as mean± SEM, n = 4 to 8.
Figure 3 Cresyl violet-stained tyrosine hydroxylase (TH)- neurons of the SNc from bregma level −3.08 to −3.40 were quantified as a
measure of non-dopaminergic neurons. Treatment with paraquat or poly(I:C) alone did not affect TH- neuron counts, but poly(I:C) pre-
treatment followed 2 days later by paraquat administration induced a significant decrease in TH- neuron counts at bregma −3.28. *P< 0.05,
relative to saline-treated controls. Data expressed as mean± SEM, n = 4 to 7.
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not influence this outcome. In general, the poly(I:C) and
paraquat combination provoked changes in morphology
that were essentially characteristic of an intermediate
microglial activation, with moderately compacted soma
with shortened and thickened projections.
To assess the oxidative potential of activated microglia,
SNc sections were stained with anti-gp91. This mem-
brane-bound enzyme is responsible for the generation of
the oxidative radical, superoxide. ANOVA showed that
gp91 activity varied significantly between treatment
groups (F(5,23) = 3.166, P< 0.05). Administration of poly(I:
C) or paraquat alone (Figure 5) induced a modest increase
in gp91 activity (P=0.06 and P=0.11, respectively, relative
to saline-treated mice). However, combined exposure of
poly(I:C) and paraquat induced a very obvious elevation of
gp91 immunoreactivity (P< 0.05), particularly in mice
that received poly(I:C) 2 days before the paraquat injec-
tions, relative to saline treatment.
Striatal assessment
Densitometry measures were used to quantify TH-positive
terminals in the striatum. Unexpectedly, there were no
differences found between groups with regard to striatal
DA terminal coverage (F< 1; data not shown).
Given the lack of effect of paraquat upon striatal term-
inals and the paucity of behavioral changes, it was of inter-
est to investigate the possibility that compensatory
processes might have been upregulated over time in re-
sponse to the pesticide exposure. To this end, striatal sec-
tions were immunostained for DCX (a measure of
immature neurons), but we found that the total number of
DCX-positive cells present in the subventricular zone
(SVZ) ipsilateral to the poly(I:C) infusion did not signifi-
cantly vary between the treatment groups (F< 1; data not
shown). Similarly, new DCX-positive neurons did not seem
to be induced to migrate from the SVZ into the striatum.
Discussion
Accumulating evidence suggests that some combination
of environmental toxins ranging from infectious insults to
heavy metals and pesticides contribute to PD [21,31-35].
Some authors have even entertained the notion that a la-
tent viral infection early in life may contribute to the onset
of the disease [36]. Indeed, post-encephalitic cases of par-
kinsonism have been reported to occur years after viral in-
fection [21,22]. It may be that exposure to immunological
challenges (viral or bacterial) provoke modest neuroin-
flammation (for example, microglial activation, cytokine
release) that over time may either: 1) cause frank neurode-
generation or 2) render DA neurons vulnerable to degen-
eration in response to subsequent environmental insults.
With regard to this second possibility, we found that the
double-stranded RNA viral analog poly(I:C) sensitized
mice to the deleterious effects of paraquat exposure.
One of the most consistent findings across human post-
mortem and animal toxin models of PD has been the asso-
ciation between strongly activated inflammatory microglia
and DA neurodegeneration [8,37-41]. Emerging data also
show that pro-inflammatory cytokines, particularly inter-
feron (IFN)-γ and tumor necrosis factor (TNF)-α, modulate
Figure 4 Substania nigra pars compacta (SNc) sections were stained with anti-Cd11b and rated on morphological appearance as
marker for microglial state. Paraquat or poly(I:C) alone promoted a modest but non-significant elevation of microglial activation state relative to
saline-treated controls. However, paralleling the TH+ changes, poly(I:C) priming followed by later paraquat exposure significantly augmented signs
of microglial activation. (A) Representative photomicrographs showing the degree of nigral microglial immunoreactivity induced by paraquat and
poly(I:C) (note that the poly(I:C)-PQ image was taken from the group that received paraquat 2 days after poly(I:C) pre-treatment). (B) Quantification
of ratings (arbitrary units) for microglial activation state. *P< 0.05, relative to saline-treated controls. Data expressed as mean± SEM, n = 4 to 5.
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the microglial response to PD relevant environmental tox-
ins [42-44]. In this study, we found that that poly(I:C) infu-
sion alone caused modest but non-significant effects upon
morphological status (using CD11b staining) and oxidative
potential (assessed by increased gp91 staining) of microglia.
This finding concurs with a previous reports indicating that
a single poly(I:C) infusion (albeit of higher concentration)
led to a decrease of TH-positive neurons in the SNc [25].
However, in the current study, the most dramatic effects
were seen within the context of paraquat exposure, with
poly(I:C) pre-treatment greatly increasing the degree of DA
neuronal loss and microglial activation in response to later
paraquat exposure.
In contrast to our previous findings using LPS priming
[12], the present results indicated that timing between poly
(I:C) priming and subsequent paraquat administration did
not seem to be particularly important to the appearance of
a sensitized response. In fact, poly(I:C) induced a protracted
activation of microglia within the SNc that was still evident
after 14 days, whereas in our previous study [12], we found
that the effects of LPS upon CD11b-positive microglia
were more transient (evident after 2 days, but returning
towards baseline by 7 days). Although the effects of LPS
and poly(I:C) were temporally distinct, the most important
finding was that the augmented SNc DA neuronal loss
was evident when exposure to the paraquat regimen
occurred at a time of heightened microglial reactivity.
However, it is noteworthy that the morphological changes
of microglial (as indicated by CD11b staining) appeared to
be most profound (although transient) with LPS priming
(involving very compact amoeboid-like cells; [12]), com-
pared with the more intermediate (but protracted) state
induced by poly(I:C).
The differences in the temporal pattern of microglial
immunoreactivity induced by poly(I:C) compared with pre-
vious reports using LPS might stem from variations in
intracellular TLR-linked proteins. Indeed, inhibition of the
TIRAP/MyD88 signaling proteins has been shown to block
TLR4 but not TLR3 signaling [45]. Moreover, bone-mar-
row-derived macrophages treated with a TLR3 agonist dis-
played an enhanced and sustained immune response (that
is, induction of type-1 IFN gene expression), relative to
macrophages treated with a TLR4 agonist [45]. In addition,
cultured human microglia were found to produce higher
levels of some pro-inflammatory cytokines when treated
with poly(I:C) compared with LPS [46].
Whatever the mechanism underlying TLR-linked path-
ways, oxidative stress factors are undoubtedly linked to
PD-like pathology occurring after toxin exposure. Indeed,
alterations in brain iron content, impaired mitochondrial
function, and antioxidant protective systems, together with
oxidative damage to lipids, proteins, and DNA, are typic-
ally seen in post-mortem brains of patients with PD and of
toxin-exposed animals [47]. Post-mortem analysis of PD
brains also showed upregulation of gp91 within the SNc
[48,49]. Importantly, gp91 is the inducible catalytic subunit
of the microglial NADPH oxidase enzyme, which in turn
is responsible for the generation of the potentially dam-
aging superoxide radical [50,51]. The fact that the most
dramatic gp91 elevation seen in the present study occurred
Figure 5 Substania nigra pars compacta (SNc) sections were stained with anti-gp91PHOX as a marker for signs of oxidative stress. In
agreement with the CD11b ratings, poly(I:C) priming followed by later paraquat treatment resulted in significantly increased expression of
gp91PHOX immunostaining relative to saline-treated controls. (A) Representative photomicrographs showing the degree of gp91PHOX
immunoreactivity in paraquat, poly(I:C), and the combination treatment groups, (note that the poly(I:C)-PQ image was taken from the group that
received paraquat 2 days after poly(I:C) pre-treatment), (B) Quantification of ratings (arbitrary scale units) of gp91PHOX immunoreactivity in the
SNc. * P< 0.05, relative to saline-treated controls. Data expressed as mean± SEM, n = 5–8.
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in poly(I:C) primed mice that also received paraquat sug-
gests that the oxidative effect of paraquat is augmented in
the context of an inflammatory microenvironment. This
finding is consistent with the importance of gp91 shown in
previous rodent studies that revealed attenuated degenera-
tive effects of paraquat after genetic or pharmacological
ablation of the NADPH oxidase subunit [48,52-54].
Although in our study, the most potent effects of para-
quat were restricted to TH-positive SNc neurons, it should
be mentioned that some TH-negative nigral neurons were
also affected. These TH-negative cells probably represent a
γ-Aminobutyric acid (GABA)ergic neuronal population
[55]. This observation suggests that paraquat-induced neu-
rodegeneration may not be entirely specific to DA neurons.
It is possible that, given the marked pro-inflammatory and
pro-oxidative state we observed in the SNc, non-DAergic
neurons can succumb to such a volatile microenvironment.
Indeed, LPS infusion alone was previously reported to de-
crease TH-negative neurons in the rat SNc [56], reinforcing
the idea that strongly reactive microglia are sufficient to in-
duce non-DAergic neuron death. It is conceivable that the
transient disruption of the blood brain barrier expected
after the surgical cannula implantation procedures could
have augmented the overall entry of paraquat into the
brain, and hence contributed to a non-specific loss of non-
TH neurons.
Although paraquat has been reported to induce dose-
dependent loss of SNc DA neurons [55], discrepant reports
exist about the degree of degeneration in striatal terminals,
with some studies reporting no effects of the pesticide
[55,57]. In the present investigation, we found that both
paraquat and poly(I:C), alone or in combination, did not
affect DA terminals in the striatum. In agreement with this
observation was the general lack of behavioral effects. In
fact, there was only a modest transient but non-significant
reduction of home-cage activity, which occurred 22 days
after the poly(I:C) infusion. Furthermore, a pole test, which
is designed to tap into forelimb and hindlimb deficits, failed
to reveal any signs of coordination deficits.
Given the unexpected lack of striatal or behavioral defi-
cits in the face of SNc soma loss, it was of interest to de-
termine whether compensatory processes might have
been provoked by poly(I:C) and paraquat. Indeed, the ex-
istence of neural stem cells and progenitors in the SVZ
[58] raises the possibility that new neurons could be
recruited into the nearby striatum after insult, as has been
reported after ischemic brain injury [59-61]. Less evidence
exists concerning the possibility of increased neurogenesis
in a PD model; however, it has been reported that -me-
thyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated
mice exhibited increased neurogenesis [62]. In the current
study, both poly(I:C) and paraquat treatment failed to in-
fluence the number of DCX-positive immature neurons
counted within the SVZ, and there was no evidence of
new neuronal infiltration into the striatum. This negative
finding might stem from the fact that, unlike another
neurotoxin, MPTP, paraquat is not believed to be taken
up by DA transporters at the terminals [63]. Alternatively,
the magnitude of the SNc soma lesion might simply have
been insufficient to affect processes at the downstream
terminals.
Conclusions
Overall, the present findings emphasize the importance of
inflammatory and oxidative factors and reinforce the idea
that PD might be triggered by cumulated exposures to
multiple environmental insults (possibly in combination
with genetic vulnerabilities). These data indicate that viral
infection might ‘set the stage’ or essentially sensitize neu-
roinflammatory responses in such as way that subsequent
environmental insults induce exaggerated effects. Future
therapies for PD might consider targeting crucial inflam-
matory mechanisms that are often triggered by environ-
mental exposures to various immune or chemical toxins.
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